Dynamic prognostic nutritional index could be a novel predictor of survival in lung cancer patients treated with nivolumab


MİRİLİ C. , PAYDAŞ S. , OĞUL A. , GÖKÇAY S. , BÜYÜKŞİMŞEK M. , YETİŞİR A. E. , ...Daha Fazla

ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, cilt.11, ss.1-6, 2020 (ESCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 11
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4328/acam20025
  • Dergi Adı: ANNALS OF CLINICAL AND ANALYTICAL MEDICINE
  • Sayfa Sayıları: ss.1-6

Özet

Aim: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint inhibitor antibody, restores antitumor antibody-disrupting PD-1-mediated signaling. Although it has a striking antitumor efficacy, factors predicting response, especially at the beginning of the immunotherapy are important owing to its side-effect profile and high cost. In this study, we aimed to evaluate the predictive value of the neutrophil-lymphocyte ratio (NLR), derived NLR (dNLR), prognostic nutritional index (PNI), carcinoembryonic antigen (CEA) and change of these parameters during nivolumab treatment in patients with non-small cell lung cancer (NSCLC).